You are performing END-TO-END ADVERSE EVENT DECOMPOSITION for the CTO. This is Round 63, responding to a CEO Round 62 audit that accepted the CE-018 capability collision theorem but identified the next P0 problem: the proposed "narrow residual" (Capability 8: clot-sensor-derived outcome prediction) is still an ABSTRACT ARCHITECTURE, not a discovery.

CEO DIRECTIVE (verbatim):
"The proposed residual 'closed-loop prediction of a specific adverse event during a specific retrieval attempt, from intraprocedural clot-sensor data fused with device-state data, triggering a specific pre-event intervention' is NOT yet a discovery. It is an abstract architecture. The machine still hasn't answered: What EXACT adverse event? What EXACT sensor signature predicts it? What EXACT intervention occurs before it? Why can't the existing sensor/control systems do that already?"

CEO SHARPENED CE-018:
"Capability novelty must be evaluated at the functional end-to-end level: input → inference → decision → physical effect → measurable outcome. Otherwise the machine can still find a 'novel' intermediate layer that is already covered by an existing end-to-end system."

CEO DIRECTIVE ON ADVERSE EVENT SELECTION:
"Pick one adverse event only. Do not search 'adverse events.' Pick one: first-pass failure, or embolization, or vessel injury, etc. Then build the full prior-art matrix around that one event."

CEO DIRECTIVE ON PRIOR ART ATTACK:
"Attack US20250186070A1 at this exact boundary. It already teaches: sensor → clot characteristics → aspiration-state control, including adherence-related characteristics. Therefore ask: What does the proposed adverse-event predictor do that this system cannot do? If the answer is merely 'predict more accurately,' that is not enough."
"Attack Clotild at the same boundary. Clotild already performs in-situ clot characterization and produces information intended to inform treatment approach. So the candidate must be downstream of generic clot characterization."

============================================================
SECTION 1: ADVERSE EVENT CANDIDATE EVALUATION
============================================================

Evaluate these 6 candidate adverse events against 4 criteria (score 1-5 each, 5 = best):
- (A) REAL-TIME PREDICTABILITY: Can the event be predicted BEFORE it occurs, during the procedure, from sensor data available before the event?
- (B) SENSOR-DATA RELEVANCE: Is the event directly predictable from clot-sensor data (composition, mechanical properties, impedance signature) rather than from imaging or post-hoc variables?
- (C) PRE-EVENT INTERVENTION FEASIBILITY: Is there a specific physical action the operator can take BEFORE the event occurs that would prevent or mitigate it?
- (D) MEASURABLE CLINICAL EFFECT: Does preventing the event produce a measurable outcome change (TICI grade, distal embolization count, 90-day mRS, sICH rate)?

The 6 candidates:
1. First-pass failure (TICI < 3 after first retrieval attempt)
2. Distal embolization (clot fragments escaping to distal vasculature during retrieval)
3. Vessel perforation (device-induced vessel wall injury)
4. Clot fragmentation (clot breaks apart during retrieval, causing embolization or failed retrieval)
5. Hemorrhagic transformation / symptomatic intracranial hemorrhage (sICH, post-procedural)
6. No-reflow phenomenon (microvascular failure despite macrovascular recanalization)

For each candidate:
- Score A, B, C, D (1-5 each)
- Total score (out of 20)
- One-sentence justification per score
- Verdict: ADVANCE / RETIRE

Then RECOMMEND the single strongest candidate. The CTO will make the final pick, but your engineering recommendation is needed.

============================================================
SECTION 2: END-TO-END DECOMPOSITION OF RECOMMENDED CANDIDATE
============================================================

For your recommended adverse event, decompose the complete causal loop:

EXACT SENSOR INPUT:
- What specific sensor modality? (impedance, force, optical, acoustic, etc.)
- What specific signal feature? (impedance spectrum slope, force gradient, OCT texture metric, etc.)
- What is the measurement geometry? (where on the clot, how many points, what temporal resolution)
- Why THIS sensor and not another?

EXACT INFERRED STATE:
- What latent state is inferred from the sensor input? (clot stiffness, friability index, adhesion strength, heterogeneity score, etc.)
- What is the inference model? (physics-based, learned, hybrid)
- What is the identifiability of this state under realistic noise? (per CE-017 — do NOT claim identifiability without testing model uncertainty)

EXACT ADVERSE EVENT PREDICTION:
- What specific adverse event is predicted? (e.g., "clot fragmentation with >2mm distal embolization within 30s of retrieval initiation")
- What is the prediction horizon? (seconds? minutes? before next pass?)
- What is the prediction output? (probability, binary alert, recommended action)
- What is the false positive / false negative tolerance?

EXACT PRE-EVENT INTERVENTION:
- What specific physical action does the operator or device take when the prediction fires?
- Is it: slow retrieval speed, switch device, add distal protection, abort and reposition, adjust aspiration pressure, inject adjunct pharmacological agent?
- Why THIS intervention and not another?
- Can the intervention be executed BEFORE the adverse event occurs? (timing feasibility)

EXACT TECHNICAL/CLINICAL EFFECT:
- What measurable outcome changes if the prediction->intervention loop is executed?
- Is it: reduced distal embolization count, improved TICI grade, reduced pass count, reduced sICH rate, improved 90-day mRS?
- How is the effect measured? (intra-procedural imaging, post-procedural CT, 90-day clinical assessment)
- What is the minimum effect size that would be clinically meaningful?

============================================================
SECTION 3: PRIOR ART ATTACK AT END-TO-END BOUNDARY
============================================================

Attack the decomposed loop against US20250186070A1 (Walk Vascular / "Clot engagement detection in thrombectomy systems"):

US20250186070A1 teaches (per Round 62 analysis):
- Multi-modal intraprocedural clot sensing (optical, acoustic, OCT/LiDAR, force/pressure, impedance)
- Closed-loop aspiration-state control (claims 6, 13, 14: activate/deactivate clot removal state based on sensor output)
- CEO states description teaches: sensor output -> clot characteristics (composition, texture, elasticity, fragility, hardness/stiffness, adherence, shape) -> aspiration state influence

For EACH step of your decomposed loop, answer:
- Does US20250186070A1 teach this step? (YES / NO / PARTIAL -- quote claim/description language)
- If YES or PARTIAL: what is the EXACT difference between US20250186070A1's teaching and your proposed step?
- If the difference is merely "more accurate prediction" or "different sensor modality" or "different threshold," state honestly that this is NOT sufficient for novelty (per CEO directive: "If the answer is merely 'predict more accurately,' that is not enough")

Then attack against Clotild/Sensome:
- Clotild teaches: impedance-based smart guidewire, in-situ clot characterization (RBC vs fibrin/platelet vs mixed), real-time during thrombectomy, intended to inform treatment approach
- For each step of your loop: does Clotild's capability already cover it?
- What does your loop do that Clotild CANNOT do?

============================================================
SECTION 4: THE CRITICAL QUESTION
============================================================

Answer the CEO's critical question directly:

"What does the proposed adverse-event predictor do that US20250186070A1 + Clotild CANNOT do?"

If the answer is:
- "Predict more accurately" -> NOT ENOUGH (CEO directive)
- "Use a different sensor modality" -> NOT ENOUGH (CE-012 semantic re-skin)
- "Predict a different event" -> MAYBE ENOUGH, but only if the event is not already predicted by existing systems
- "Enable a different intervention" -> MAYBE ENOUGH, but only if the intervention is not already enabled by existing systems
- "Produce a different measurable outcome" -> MAYBE ENOUGH, but only if the outcome is not already produced by existing systems
- "Enable a NOVEL causal loop that does not exist in any end-to-end system" -> THIS IS THE ONLY SUFFICIENT ANSWER

State honestly which category your answer falls into.

============================================================
SECTION 5: KILL OR SURVIVE?
============================================================

Based on Sections 1-4:
- KILL: The narrow residual is also dead. The end-to-end loop is already covered by US20250186070A1 + Clotild. Record CE-019 (end-to-end functional novelty test). Slot 5 returns to EMPTY.
- CONDITIONAL SURVIVAL at END-TO-END SCOPE: A specific end-to-end loop survives that is demonstrably absent from US20250186070A1 + Clotild. State exactly what the loop is, what evidence would confirm it, and what the surviving claim would look like.
- PROMOTE: The candidate survives as a full invention. (Extremely unlikely given the CEO audit, but state if so.)

Do NOT make the strategic decision -- the CTO decides. State the engineering case clearly.

CONSTRAINTS:
- Be adversarial: try to KILL the narrow residual. The CTO wants honesty, not rescue.
- Do NOT use "retrieved-clot" or "physical signature" as novelty loopholes (CE-012).
- Do NOT claim novelty for an intermediate layer that plugs into an existing end-to-end system (CE-018 sharpened).
- If you cannot assess a step due to missing data, mark INCONCLUSIVE.
- Per CE-017: if you propose a latent state to infer, state the identifiability survival conditions explicitly.

OUTPUT FORMAT: Plain text, no emojis. Target ~2500-3500 words total. Start with "===== ROUND 63 END-TO-END DECOMPOSITION =====".
